A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 11 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs IMM 2902 (Primary)
Indications Advanced breast cancer; Gastric cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors ImmuneOnco Biopharma

30 Oct 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
30 Oct 2024 Status changed from recruiting to suspended, due to a business decision to deprioritize this project and with no safety concerns. The sponsor decided to stop the study.
21 Jul 2022 Planned End Date changed from 1 Jun 2023 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com